BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25869080)

  • 1. Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.
    Malik N; Baur B; Winter G; Reske SN; Beer AJ; Solbach C
    Mol Imaging Biol; 2015 Dec; 17(6):777-85. PubMed ID: 25869080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Labeling PSMA
    Eppard E; Homann T; de la Fuente A; Essler M; Rösch F
    J Nucl Med; 2017 Mar; 58(3):432-437. PubMed ID: 28082433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and preclinical evaluation of an Al
    Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
    Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
    Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [
    Zha Z; Choi SR; Ploessl K; Alexoff D; Zhao R; Zhu L; Kung HF
    Bioconjug Chem; 2021 May; 32(5):1017-1026. PubMed ID: 33872489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by
    Wurzer A; Di Carlo D; Schmidt A; Beck R; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2020 May; 61(5):735-742. PubMed ID: 31862804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automatic radiosynthesis and preclinical evaluation of
    Zhou W; Huang S; Jiang Y; Hu K; Wang L; Han Y; Wu H
    Amino Acids; 2021 Jun; 53(6):929-938. PubMed ID: 34014365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of
    Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
    Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
    Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.